Zhizi Biotech

Zhizi Biotech is an innovative biotechnology company based in Shanghai, China, focused on the development of next-generation gene-editing technologies and mRNA-based therapeutics. The company specializes in creating proprietary, high-precision gene-editing tools, including novel nucleases and sophisticated lipid nanoparticle (LNP) delivery systems. Their core technology platform aims to overcome existing limitations in gene therapy by providing safer and more efficient in vivo editing capabilities. Zhizi Biotech's research pipeline primarily targets metabolic diseases and rare genetic disorders, with lead programs addressing conditions such as hyperlipidemia and amyloidosis. Backed by prominent venture capital firms, the company is advancing its lead candidates through the pre-clinical phase to establish a robust clinical portfolio.